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Atopic dermatitis (AD) is a common chronic inflammatory skin disorder and a major manifestation of allergic disease.
AD typically presents in early childhood often preceding the onset of an allergic airway disease, such as asthma or hay
fever. We previously mapped a susceptibility locus for AD on Chromosome 3q21. To identify the underlying disease
gene, we used a dense map of microsatellite markers and single nucleotide polymorphisms, and we detected
association with AD. In concordance with the linkage results, we found a maternal transmission pattern. Furthermore,
we demonstrated that the same families contribute to linkage and association. We replicated the association and the
maternal effect in a large independent family cohort. A common haplotype showed strong association with AD (p ¼
0.000059). The associated region contained a single gene, COL29A1, which encodes a novel epidermal collagen.
COL29A1 shows a specific gene expression pattern with the highest transcript levels in skin, lung, and the
gastrointestinal tract, which are the major sites of allergic disease manifestation. Lack of COL29A1 expression in the
outer epidermis of AD patients points to a role of collagen XXIX in epidermal integrity and function, the breakdown of
which is a clinical hallmark of AD.
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Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin
disease that is characterized by intensely itchy skin lesions.
AD is one of the most common chronic diseases in childhood
affecting 10%–20% of children in industrialized societies [1],
with a steady increase over the past decades [2,3]. Along with
asthma and hay fever, AD is commonly associated with an
abnormal immune response and the formation of allergy
antibodies (IgE) against innocuous environmental allergens.
AD is often the first clinical manifestation of allergic
disease. The onset of disease is typically observed during the
first two years of life [4]. For the majority of affected children,
AD heralds a lifetime of allergic disease. A susceptible child
commonly passes a characteristic sequence of transient or
persistent disease stages that is known as the ‘‘atopic march’’
which begins with AD and food allergy in the young infant
and continues with the development of allergic airways
disease later in childhood and adulthood [5]. The close
familial and intra-individual association of the allergic
disorder strongly suggests shared genetic etiology.
A strong genetic component in allergic disorders has been
recognized almost a century ago. Cooke and van der Veer first
reported that the relatives of patients are at significantly
increased risk of developing allergic disease [6]. Even today, a
positive family history for allergic disorders is the single
strongest predictor for the development of AD [7]. Additional
evidence for the importance of genetic factors in atopic
disease comes from twin studies. The concordance rate for
AD among monozygotic twins of about 80% far exceeds the
concordance rate of 20% observed among dizygotic twins
[8,9]. These data clearly indicate that the genetic contribution
to the expression of AD is substantial. Furthermore, studies
on the vertical transmission of AD and atopic disease show
that children are more likely to inherit these disorders if the
mother is affected (parent-of-origin effect) [10]. The pre-
dominance of maternal inheritance may be due to environ-
mental factors such as uterine milieu or breast feeding, but
they may also arise due to genetic mechanisms such as parent-
specific gene expression (genomic imprinting) [11].
AD and atopic disorders are regarded as multifactorial
conditions, the onset and severity of which are influenced by
both genetic and environmental factors. The data are
consistent with an immune etiology shared by all allergic
diseases and a congenital target organ defect, the penetrance
of which is modified by multiple environmental factors
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during early childhood. The identification of genes under-
lying AD and allergic disorders has the capacity to define
primary physiologic mechanisms, thereby clarifying disease
pathogenesis, identifying pathways and targets for therapeu-
tic intervention.
Although several genome-wide linkage screens for AD have
been conducted [12–14], there was no substantial overlap
between the identified regions of highest linkage, and the
underlying genes remained elusive [15]. We have previously
mapped a major susceptibility locus for AD on Chromosome
3q21 [16]. Here we report the identification and character-
ization of a novel epidermal collagen gene as the underlying
disease gene.
Results
To narrow the candidate region spanning 12.75 centiMor-
gans (cM) (13.5 Mb) on Chromosome 3q21 (Figure 1A), 96
additional microsatellite markers at an average distance of
140 kb were genotyped in 199 affected sibling families with
AD from the original linkage scan. Linkage analysis yielded a
1-lod support interval of 5.4 Mb between the markers
M3CS075 and M3CS233 (Figure 1B). Subsequently, we con-
ducted an association scan of the 5.4-Mb region using 212
single nucleotide polymorphisms (SNPs) at an average
distance of 25.5 kb (Table S1). The SNPs were selected
primarily to cover known and predicted genes. Because we
had observed a strong maternal effect in the linkage study
[16], we chose a family-based association analysis that allowed
us to search for risk alleles preferentially transmitted from the
mother [17]. Two adjacent SNPs, rs5852593 (p ¼ 0.0079) and
rs1497309 (p ¼ 0.016), located 36 kb apart, were associated
with AD (Table S1 and Figure 1B). To define the critical
region, we typed 16 additional SNPs. Eight of these markers
showed association with AD and a maternal transmission
pattern to affected children, which was consistent with our
previous linkage results (Table 1). The strongest association
with a single marker was observed for rs4688761 (pall¼ 0.0016,
pmaternal ¼ 0.0006). We selected eight markers spanning 96 kb
that were associated with AD and carried nonredundant
information based on the linkage disequilibrium (LD) in the
region, and we performed haplotype analysis which confirmed
the results (transmissions (T)all:non-transmissions (NT)all ¼
222:168, pall¼ 0.0076, Tmat:NTmat¼ 105:68, pmaternal¼ 0.0070).
In addition, we assessed the significance of the difference in
maternal-versus-paternal haplotype over transmissions em-
pirically using the permutation procedure for parent-of-
origin transmission disequilibrium test (TDT) implemented in
PLINK (P_POOmaternal emp¼ 0.014) [18].
Next, we investigated whether the observed association
accounted for the linkage in the region. We used the marker
that had shown the strongest association, rs4688761, to
identify 73 of the 199 families from the original linkage scan
in whom the disease-associated allele had been transmitted to
affected offspring. Nonparametric linkage analysis in the 73
associated families yielded significant evidence for linkage
(Zall¼4.18 versus 4.31 in the complete cohort), demonstrating
that the majority of the linkage signal was attributable to
these families. The significance of this finding was assessed by
performing nonparametric linkage analysis in 10,000 random
selections of 73 families. An empirical significance level was
calculated as the proportion of replicates for which the
maximum Zall score was equal or greater than that obtained
in the actual analysis. The probability of obtaining a Zall score
of 4.18 by chance in a random selection of 73 families was
estimated by 10,000 simulations to be 0.027.
To confirm the association result, we used a large
independent replication set consisting of 292 complete
nuclear families including 481 children with AD. We
genotyped the selected eight SNPs covering an interval of 96
kb that were associated with AD in the discovery dataset. We
confirmed the association with AD across all markers with the
strongest association with AD observed for marker A36637742
(p ¼ 0.00038), which also showed a significant overtransmis-
sion of the maternal allele (p ¼ 0.0013) (Table 2). The
association remained significant after correction for multiple
testing. For each marker, it was the more common allele that
was overtransmitted. Haplotypes were constructed over the
region, which confirmed the association with AD and showed
that this phenotype is associated with the overtransmission of
the most common haplotype (haplotype frequency 65%,
Table 3), and of the maternal allele (pmaternal ¼ 0.000025 for
AD, P_POOmaternal emp ¼ 0.033). Next, we compared the AD
status among the parents: in the discovery cohort, significantly
more mothers (n¼ 63) than fathers (n¼ 19) suffered from AD
(odds ratio [OR] 4.39, 95% confidence interval [CI] 2.51 – 7.68,
p¼ 5.463 108). Similarly, in the replication cohort, mothers
(n ¼ 83) were significantly more frequently affected with AD
than fathers (n ¼ 55) (OR 1.71, 95% CI 1.16 – 2.52, p ¼ 8.33
103). To assess whether the parent-of-origin effect that was
observed originated from the discrepancy in AD prevalence
among the parents, we compared haplotype transmissions
from affected and unaffected mothers. In the discovery
cohort, the excess in maternal transmissions was not
predominantly attributable to affected mothers (T:UT ¼
24:21, p ¼ 0.14) compared to unaffected ones (T:UT ¼ 81:47,
p¼0.0059). Similarly, affected mothers (T:UT¼25:17, p¼0.14)
of the replication cohort did not contribute a larger trans-
mission excess than the unaffected ones (T:UT ¼ 70:29, p ¼
0.00013). We conclude that the observed maternal over-
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Author Summary
Atopic dermatitis (AD, eczema) is a common chronic inflammatory
skin disorder and a major manifestation of allergic disease. Typically,
AD first occurs in early childhood, often preceding the onset of
allergic airways disease, such as asthma and hay fever. A family
history of allergic disorders is the single strongest predictor for AD,
showing that genetic factors play a major role in the disease
development. We have previously mapped a disease locus for AD on
Chromosome 3q21, Now we have used a dense map of micro-
satellite markers and single nucleotide polymorphisms (SNPs) to find
the underlying disease gene. We identified genetic markers in a
subregion that showed association with AD, and replicated this
finding in a large independent family cohort. The associated region
contained a single gene, COL29A1, which encodes a novel collagen.
We demonstrate that AD patients lack COL29A1 expression in the
outer epidermis, implicating collagen XXIX in epidermal integrity
and function. The gene expression pattern of COL29A1 in other
organs, including the lung and the gut, suggests that this gene
could have a role in a wider spectrum of allergic diseases and may
provide a molecular link between AD and respiratory airways
disease and food allergies.
transmission pattern in both cohorts was not due to the
higher AD prevalence among mothers.
A database search within the associated 96-kb interval
revealed a single predicted gene, FLJ35880, extending 11.6 kb
into the associated region. No other expressed sequence tag
was detected. To identify any additional transcripts, we used
putative exons predicted with The National Center for
Biotechnology Information (NCBI) Modelmaker within and
bordering the critical region to perform rapid amplification
of cDNA ends (RACE) from human skin mRNA. We thus
identified a single transcript of 9226 bp that consisted of 42
exons (Figure 1D) and included all eight exons of FLJ35880.
The corresponding gene spanned 139 kb of genomic
sequence and completely encompassed the associated region.
Pairwise LD measures (D9) of the genotyped markers
indicated that the gene was contained within one 170-kb
region of increased LD (Figure 2), whereas the neighboring
genes, LOC440978 and LOC131873, were located in separate
blocks. The LD structure was consistent with the data for the
European population in the HapMap database (Figure S1)
[19]. The size of the transcript was confirmed by Northern
blot hybridization with an FLJ35880-specific probe detecting
a single transcript of 9.6 kb in human skin mRNA
(unpublished data), which was in good agreement with the
RACE experiments.
The open reading frame yielded a protein of 2614 amino
acids with an estimated molecular weight of 289.9 kDa. The
predicted protein contained a collagenous domain in the
central part and was therefore classified as a new member of
the collagen superfamily, collagen XXIX. A BLAST search
revealed the human collagen VI alpha 3 chain as its closest
neighbor (32% identity). Homology with collagen VI alpha 3
was further strengthened by a similar domain architecture
consisting of six N-terminal and three C-terminal von
Willebrand factor–type A domains (vWAs) flanking a short
collagen triple helix (Figure 1E), and an 18–amino acid
secretion signal [20]. Sequence analysis of all 42 exons in 46
unrelated children with AD and 2 unaffected individuals
revealed 13 common and six rare sequence variations
(frequency ,2%) predicted to cause nonsynonymous amino
acid substitutions (Table S2). Four variants were located
within the triple helix repeat of a collagen domain, however
none of them changed the first glycine residue in the
repeating sequence patterns (Gly-X-Y), which is critical for
Figure 1. Positional Cloning Strategy for the AD Disease Gene on Chromosome 3q21
(A) The candidate region spanned 12.75 cM between markers D3S1303 and D3S1292. The y-axis depicts the GENEHUNTER nonparametric Zall as
previously reported [16].
(B) Fine mapping with 96 microsatellite markers narrowed the interval to 5.4 Mb between markers M3CS075 and M3CS233. An association scan using
212 SNPs of the region revealed association of AD with two adjacent SNPs, rs5852593 and rs1497309. Genotyping of 16 additional SNPs refined the
associated region.
(C) Genomic positions of the 42 exons of COL29A1 are shown. The gene entirely encompasses the associated region.
(D) The COL29A1 mRNA consists of 9226 bp. Translation start site and stop codon are indicated.
(E) The predicted open reading frame encodes a protein of 2614 amino acids including a secretion peptide (SP), six N-terminal and three C-terminal
vWAs, flanking a short collagen triple helix.
doi:10.1371/journal.pbio.0050242.g001
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triple helix formation [21]. In addition, we performed in
silico comparisons of the six variants located within a vWA
with the crystal structure of the human vWF A3 domain. One
variant, V669G, affects an amino acid within a highly
conserved stretch of eight amino acids. The mutation of an
adjacent amino acid within this conserved region of a vWA in
the homologous gene COLVIA1 has been reported to cause
the monogenic muscle disorder Bethlem myopathy [22]. This
variant, however was rare (allele frequency 1,3%). One
additional variant (E455K) is located in a region predicted
to be important for integrin–collagen interaction, and
another one (M56T) is located in a helix near a rather
conserved region that may also affect protein–protein
interaction. All coding SNPs were genotyped in the discovery
cohort. Four of them showed a positive association with AD
that did, however, not account for the observed haplotype
association (Table S2).
Gene expression analysis in human tissues revealed a
tissue-specific expression pattern of COL29A1. The highest
expression was observed in the skin, but also in the lung, small
intestine, colon, and testis (Figure 3A). Overall, COL29A1
expression is moderately low compared to more abundant
epidermal transcripts such as keratin 10 (unpublished data).
To specify the expression sites in the layers of the skin and
to assess the role of collagen XXIX in AD, we performed in
situ hybridization using a COL29A1-specific cRNA-probe on
Table 1. Results of the ASPEX sib_TDT for SNPs in the Region of COL29A1 for AD in the Discovery Cohort
Locus Position on
Chromosome 3
Location in
COL29A1
MAF Major/ Minor
Allele
All Transmissions Paternal Maternal
T NT v2 p-Value T NT v2 p-Value T NT v2 p-Value
rs1349747 131,543,410 59 18.0 A/G 129 99 3.95 n.s. 48 43 0.27 n.s. 72 47 5.25 n.s.
rs1869319 131,547,433 exon 1 9.4 C/T 80 63 2.02 n.s. 36 32 0.24 n.s. 80 63 2.38 n.s.
rs13095825 131,549,247 intron 1 36.6 T/C 222 167 7.78 0.0072 84 56 5.6 0.024 99 72 4.26 0.047
rs1453243 131,575,875 intron 2 30.5 G/A 187 149 4.3 n.s. 68 49 3.09 n.s. 91 72 2.21 n.s.
rs5852593 131,580,335 intron 3 24.3 del/T 157 111 7.9 0.0079 71 45 5.83 0.026 67 47 3.51 0.045
rs16845861 131,581,039 exon 4 24.4 G/A 166 123 6.4 0.018 68 49 3.09 n.s. 79 55 4.3 0.037
rs1453242 131,586,229 intron 4 24.3 C/T 171 123 7.84 0.0099 75 51 4.57 0.045 79 55 4.3 0.036
rs10212372 131,586,896 exon 5 24.4 A/G 165 123 6.12 0.021 68 50 2.75 n.s. 78 54 4.36 0.037
A36603217 131,590,753 intron 6 22.6 A/G 161 118 6.63 0.015 73 56 2.24 n.s. 72 46 5.73 0.02
rs10934938 131,596,325 intron 7 22.0 T/G 156 114 6.53 0.013 71 54 2.31 n.s. 72 47 5.25 0.019
rs4688761 131,607,679 exon 16 28.6 T/C 187 128 11.05 0.0016 76 56 3.03 n.s. 79 40 12.78 0.0006
A36624476 131,612,012 exon 20 13.5 G/C 109 83 3.52 n.s. 50 44 0.38 n.s. 50 30 5 0.028
rs1497309 131,616,310 intron 22 28.7 C/T 185 137 7.16 0.016 76 57 2.71 n.s. 76 47 6.84 0.013
rs7628563 131,617,253 intron 23 15.1 A/G 123 97 3.07 n.s. 53 38 2.47 n.s. 53 42 1.27 n.s.
A36637742 131.625.270 intron 28 27.8 del/T 184 146 4.4 0.05 75 62 1.44 n.s. 75 53 4.43 0.040
rs1566136 131,634,657 intron 33 28.4 A/G 191 154 3.97 n.s. 85 64 2.96 n.s. 76 60 1.88 n.s.
rs9883988 131,645,085 exon 36 6.3 G/A 56 35 4.85 0.049 31 18 3.45 n.s. 19 11 2.13 n.s.
rs322113 131,670,507 exon 38 7.8 C/T 46 52 0.37 n.s. 27 25 0.08 n.s. 17 25 1.52 n.s.
rs322115 131,672,716 intron 39 18.2 A/T 116 99 1.34 n.s. 48 45 0.1 n.s. 52 38 2.18 n.s.
rs819091 131,678,260 intron 40 23.7 G/A 153 118 4.52 n.s. 67 55 1.18 n.s. 62 39 5.24 0.025
rs7624712 131,686,432 39 11.6 A/G 75 74 0.01 n.s. 33 38 0.35 n.s. 37 31 0.53 n.s.
MAF, minor allele frequency.
T, number of transmissions.
NT, number of nontransmissions.
n.s., not significant.
doi:10.1371/journal.pbio.0050242.t001
Table 2. Association Analysis of Single Markers for Atopic Dermatitis in the Replication Dataset
Locus Major/ Minor
Allele
All Transmissions Paternal Maternal
T NT v2 p-Valuea T NT v2 p-Value T NT v2 p-Value
rs13095825 T/C 218 174 4.94 0.028 81 66 1.53 0.18 95 66 5.22 0.022
rs16845861 G/A 177 119 11.36 0.00077* 68 46 4.25 0.038 82 46 10.12 0.0014*
rs10212372 A/G 174 117 11.16 0.00093* 68 46 4.25 0.035 81 46 9.65 0.0017*
A36603217 A/G 180 118 12.9 0.00040* 81 52 6.32 0.013 77 44 9 0.0023*
rs10934938 T/G 182 122 11.84 0.00063* 83 54 6.14 0.019 76 45 7.94 0.005*
rs4688761 T/C 208 145 11.24 0.00082* 94 67 4.53 0.03 88 52 9.26 0.0031*
A36637742 del/T 204 139 12.32 0.00038* 84 57 5.17 0.028 89 51 10.31 0.0013*
rs9883988 G/A 75 43 8.68 0.0019* 37 23 3.27 0.055 37 19 5.79 0.0091
a p-values of the ASPEX sib TDT for atopic dermatitis for all, paternal, and maternal transmissions for the major allele. None of the paternal transmissions were significant after simulation. *
p-values significant after correction for multiple testing.
T, number of transmissions.
NT, number of nontransmissions
doi:10.1371/journal.pbio.0050242.t002
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skin biopsies of five patients with AD and five healthy patients
(controls). In normal skin, COL29A1 was exclusively expressed
in the epidermis with the strongest staining in the suprabasal
viable layers. In contrast, the skin of patients with AD
revealed a striking absence of COL29A1 mRNA staining in the
most differentiated upper spinous and granular layers (Figure
3B and Figure S2). No significant difference in the expression
of COL29A1 was observed comparing patients with AD to
controls (1.28- 6 0.53-fold down-regulation in AD patients,
p ¼ 0.41) using quantitative Taqman reverse-transcriptase
Figure 2. Pairwise LD Values (D9) Between 28 SNPs Based on Genotypes of the Founders in the Discovery Cohort
Boxes contain the LD values (D9) between the respective markers indicated on top. Higher LD values correspond to a darker shade of red. Positions on
Chromosome 3 are given in Mb; 131.547 denotes the start and 131.686 the end of COL29A1 on the genomic sequence. Boxes on the horizontal bar
represent the 42 exons of COL29A1.
doi:10.1371/journal.pbio.0050242.g002
Table 3. Haplotype Analysis for AD in the Replication Dataset
rs13095825 rs16845861 rs10212372 A36603217 rs10934938 rs4688761 A3667742 rs9883988 Atopic Dermatitis
freq. fam. S E(S) Var(S) Z p-value
T G A A T . . 0.62 127 429.5 403.4 95.8 2.66 0.0078*
. G A A T T . 0.68 120 432.3 397.8 89.2 3.65 0.00025*
A A T T del 0.66 115 428.3 390.7 87.2 4.02 0.000059*
. . A T T del G 0.70 114 415.9 381.4 89.20 3.65 0.00026*
fbat statistic (Z) for 5-marker haplotype transmissions in the replication set adjusted for the correlation among siblings, reporting haplotype frequency (freq.) the number of informative
families (fam.), the distribution (S), the expected distribution (E(S)), and the variance (Var(S)). * p-values significant after correction for multiple testing.
doi:10.1371/journal.pbio.0050242.t003
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(RT)-PCR. These results indicate that while differences in
mRNA quantity were not detected, AD patients show a
distinct abnormal cellular distribution pattern of COL29A1
expression in the differentiated outer epidermis.
We generated a polyclonal antibody to visualize the
collagen XXIX protein in the skin of five patients with AD
and five normal controls, including four and three of each
group, respectively, in whom in situ analysis was performed.
Consistent with the in situ findings, we observed collagen
XXIX staining in the differentiated suprabasal layers of the
epidermis in normal human skin and a remarkable absence of
staining in the most differentiated upper spinous and
granular layers (Figure 4 and Figure S3).
Discussion
In a whole-genome linkage scan for AD, we previously
identified a susceptibility locus on human Chromosome 3q21.
The candidacy of this chromosomal region was further
supported by Bradley et al., who mapped a locus for AD
severity in close proximity (3q14) in a Swedish population
[13]. By positional cloning, we have now identified the
disease-causing gene, COL29A1, which encodes a novel
epidermal collagen.
The disease gene was located in a two-staged investigation
consisting of systematic linkage and association scanning of
the region and subsequent confirmation of the association in
a large, independent, replication dataset. In the first stage, we
genotyped additional microsatellite markers in the candidate
region, which narrowed the initial 12.75-cM linkage interval
to 5.4 Mb. The association analysis with an average marker
distance of 25.5 kb, finally, revealed an association that was
confined to a haplotype block of 170 kb, which included a
single gene, COL29A1. Pairwise LD measures indicated LD
across the entire gene and defined two subblocks of increased
LD. The strongest association was observed within the 96-kb
subblock encoding the collagenous domain and the C
terminus of collagen XXIX. A rapid decay of LD at the
borders of the COL29A1 haplotype block and lack of
association of the SNPs located within the neighboring genes
clearly limited the association to COL29A1. In addition, we
demonstrated in the discovery dataset that the families that
contributed to the association of SNP rs4688761 with AD also
accounted for most of the linkage signal. This finding
corroborated that variants in COL29A1 explained the
Figure 3. Gene Expression Analysis of COL29A1
(A) RT-PCR analysis of collagen XXIX in human tissues. (B) In situ gene
expression analysis of COL29A1 in AD skin. In situ hybridization results of
a COL29A1-specific antisense probe on cryostat sections (5 lm thick) of
an AD skin biopsy (left) and a normal human control (right) are shown.
COL29A1 mRNA detected by the digoxigenin-labelled probe is stained in
blue (BCIP/NBT staining). The arrows point the different gene expression
in the upper spinous and granular layer of the epidermis of an AD
patient and a normal human control. Stratum basale (SB), stratum
spinosum (SS), stratum granulosum (SG), and stratum corneum (SC) are
indicated.
doi:10.1371/journal.pbio.0050242.g003
Figure 4. Immunohistochemical Analysis of Collagen XXIX Expression in
AD Skin
Cryostat sections (5lm thick) of an AD skin biopsy (A) and a normal
human control (B) are shown. In normal, human skin, collagen XXIX is
expressed in the epidermis. In patients with atopic dermatitis, a striking
lack of collagen XXIX staining was observed in the viable outermost
spinous and granular layers of the epidermis (arrow). Stratum basale (SB),
stratum spinosum (SS), stratum granulosum (SG), and stratum corneum
(SC) are indicated. Collagen XXIX was stained with fuchsin (red). Sections
were counterstained with hematoxylin (blue).
doi:10.1371/journal.pbio.0050242.g004
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previously reported linkage of AD to 3q21 [16]. Finally, we
confirmed association in a large independent family cohort,
making COL29A1 the first AD susceptibility gene, to our
knowledge, that is identified by positional cloning.
Consistent with the linkage analysis, we found a maternal
transmission pattern to affected offspring in both family
cohorts. Although the sexes were equally represented among
the affected children of both cohorts, we observed a marked
maternal preponderance in AD status among the parents in
both cohorts. This finding clearly supports the notion of a
maternal effect. It may, however, also raise the question
whether the maternal overtransmission pattern observed for
the COL29A1 haplotype was due to the different prevalence
of AD in mothers and fathers. This is unlikely to be the case,
because the analytical tools used in this study, nonparametric
linkage and TDT, do not take into account the parental
phenotype. Furthermore, we showed that the observed
maternal effect was not predominantly attributable to trans-
missions from affected rather than unaffected mothers.
Although parent-of-origin effects have not previously been
reported for genes from Chromosome 3q21, they have been
observed at other loci influencing allergic disease [23]. Tissue-
specific imprinting of genes encoding extracellular matrix
(ECM) proteins has been reported in the mouse [24], and
their disruption has been shown to impair skin structure and
function [25]. Interestingly, COL29A1 is expressed in human
placenta, an organ of embryonic origin. Apart from classic
genomic imprinting mechanisms, maternal effects may be
due to an interaction of the child’s genotype with the
maternal environment during prenatal life.
Sequencing of the exons and promoter region revealed 19
nonsynonymous coding SNPs, six of which were located
within a vWA. In silico analysis of these variants revealed only
one rare mutation altering a highly conserved amino acid, but
all of them may affect protein–protein interaction. None of
the nonsynonymous coding SNPs explained the observed
association on its own. It has been demonstrated in other
complex diseases that multiple independent variants may
occur in a single disease gene [26]. It is therefore possible that
several variants or combinations thereof which are associated
with the most common haplotype of COL29A1 are involved in
the disease pathogenesis. The functional influence of the
associated variants remains to be determined.
Involvement of COL29A1 in AD is further supported by its
tissue- and cell-specific expression pattern. Like COL29A1, a
growing number of collagens recently identified show a
restricted expression pattern. These are not mainly found in
fibrous connective tissue, but rather in the ECM of more
specialized tissue structures pointing to a distinctive function
of these proteins [27]. Highest COL29A1 expression was
observed in the skin, but also in other epithelial tissues such
as the lung, small intestine, and colon, which are the main
manifestation sites of allergic disorders, including asthma and
food allergies. This gene expression pattern might indicate a
role of collagen XXIX in a wider spectrum of allergic diseases
and suggests a molecular link between AD, respiratory
airways disease, and food allergies, which are epidemiologi-
cally closely associated [28,29].
In human skin, collagen XXIX was detected throughout the
viable layers of the epidermis with an increase toward the
differentiated cells of the granular layer. Comparative
expression analysis of COL29A1 by in situ hybridization and
immunohistochemistry in skin biopsies of patients with AD
and healthy controls revealed a distinct lack of COL29A1
mRNA and protein in the outer viable layers of the epidermis.
The process of epidermal stratification is tightly regulated by
an increasing gradient of extracellular Ca2þ concentration
and a specific special and temporal expression pattern of
transcriptional regulators [30]. Our findings indicate that the
specific cellular milieu acquired during terminal epidermal
differentiation affect the regulation or degradation of
COL29A1 mRNA in the outer epidermis. However, our
findings do not allow us to distinguish between these two
processes.
Lack of collagen XXIX in the outer epidermis of AD
patients indicates that a defective ECM may give rise to the
disease, proposing a new pathomechanism for AD. Collagens
are the most abundant ECM proteins in vertebrates and play
a crucial role in maintaining tissue integrity. Their impor-
tance for tissue function has been highlighted by the wide
spectrum of human diseases caused by mutations in collagen
genes [31]. Although a large number of collagens in the
connective tissue–rich dermis have been characterized, little
is known about collagens in the ECM of the epidermis [32,33].
Collagen XXIX belongs to the vWA containing collagens.
They form filaments with globular domains containing the
vWA motifs, which are involved in protein–ligand interac-
tions for the organization of tissue architecture and cell
adhesion [34]. It is therefore conceivable that collagen XXIX
plays an important role in keratinocyte cohesion. Lack of
collagen XXIX may facilitate antigen penetration through the
skin, which may explain the association found between
COL29A variants and allergic sensitization, a common feature
in AD patients [35]. Recent findings indicate that structural
and functional integrity of the epidermis is a key factor in the
development of AD [36] and in the disease progression to
allergic airways disease [37].
Furthermore, ECM collagens influence the migration of
epidermal antigen-presenting Langerhans cells and T cells
[38,39] and may thus play an important role in the initiation
and maintenance of cutaneous immune responses. In
addition, ECM collagens participate in immune regulation
by binding to inhibitory immune receptors [40], rendering
collagen XXIX an interesting novel susceptibility gene for
AD. Impairment of the immune defense function of the skin
is a clinical hallmark of AD. Patients with AD show a
diminished resistance against microbes resulting in the
colonization of nonlesional skin with Staphylococcus aureus in
nearly 90% of patients and an increased susceptibility to
bacterial and viral skin infections [41]. Our findings led to the
identification of collagen XXIX as a novel component of the
epidermal ECM and propose a new disease mechanism in the
etiology of atopic dermatitis and allergies.
Materials and Methods
Human subjects. The diagnosis of AD was made according to
standard criteria, as previously described [16]. Recruitment was
restricted to patients with an age of onset below 2 y and moderate to
severe disease expression. Total IgE levels and levels of specific IgE
against 12 common environmental allergens were determined using
ImmunoCAP (Phadia AB; http://www.phadia.com/). Allergic sensitiza-
tion was defined as either the presence of specific IgE to at least one
allergen (detection limit 0.35 kU/l) or a total serum IgE level elevated
above the age-specific norm. The institutional review boards of the
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participating centers approved the study protocol and informed
consent was obtained from all probands or their legal guardians.
One discovery study sample and one replication sample were
investigated. All families were of European origin. The discovery data
set consisted of 199 complete affected sibling families composed of
427 children with AD that were studied in the original genome scan.
[16] The replication set consisted of 292 families including 481
children with AD with an age of onset 2 y and moderate to severe
disease expression. Among AD patients in the discovery and the
replication cohorts, the proportion of boys was 52% and 50.9%, and
the proportion of children with allergic sensitization was 74% and
72.1%, respectively.
Punch biopsies of human skin were obtained from six patients with
AD and 7 healthy donors aged 24–55 y with written informed
consent. Specimens were prepared for in situ hybridization and
immunohistochemistry as described below.
Microsatellite genotyping. In the first stage, fine mapping with
microsatellite markers was performed in the discovery dataset. 96
short tandem repeat markers were selected within the interval
between D3S1303 (126.07 cM) and D3S1292 (138.82 cM) from the
Genethon (http://www.genethon.fr/) and Marshfield (http://research.
marshfieldclinic.org/genetics/) databases, or were identified by screen-
ing human genome sequence data for short tandem repeats.
Fluorescence-based semi-automated genotyping was performed as
previously described [16]. Primer sequences, amplification condi-
tions, and allele size are available on request.
Association scan with SNPs. We performed an association scan of
the 5.4-Mb region using 212 SNPs at an average distance of 25.5 kb.
The SNPs were selected from the NCBI database (http://www.ncbi.
nlm.nih.gov/projects/SNP/) to cover known and predicted genes. To
determine the allele frequency of the polymorphisms, we amplified
600 to 800 bp surrounding each SNP by PCR for resequencing in 31
unrelated Caucasian individuals. Markers with a minor allele
frequency (MAF) of .5% were selected for genotyping. To identify
functional variants in collagen XXIX, we sequenced all 42 exons
including the exon–intron boundaries and 5.1 kb of the promoter
region in 46 unrelated patients with AD and two controls. Sequencing
was performed on an ABI3730 DNA sequencer (Applied Biosystems;
http://www.appliedbiosystems.com) using standard procedures.
We carried out SNP genotyping using TaqMan allelic discrim-
ination, with probes and primers designed and synthesized by the
supplier (Applied Biosystems), or by pyrosequencing using PSQ HS
96A (Pyrosequencing AB; http://www.biotagebio.com/). The averages
genotyping success rate was 97.9%. All primer and probe sequences
are available on request.
Statistical analysis. We performed linkage analysis of the micro-
satellite data using Genehunter V. 2.1 [42]. Each SNP was checked for
compliance with Hardy-Weinberg equilibrium (HWE) in the parent
population using a v2 test, and those markers that were not in HWE
were excluded from the analysis. We calculated pairwise LD between
each marker pair using the D9 statistic.
In view of the strong imprinting effect at our locus, we conducted
family-based association tests, because this strategy allows us to
determine the parental origin of an associated allele. In the affected
sibling families, we used the sib_TDT of the ASPEX software that
performs a permutation procedure to calculate empirical p-values
that are independent of linkage within families [17]. Furthermore, to
assess the significance of the maternal effect, we calculated empirical
p-values for the difference in maternal versus paternal haplotype
transmissions using the parent-of-origin TDT implemented in PLINK
[18].
The sib_TDT was also used in the analysis of eight markers in the
replication dataset. The significance level of the replication results
was assessed empirically. Using all pedigrees and all genetic markers
used in the actual analysis, we generated 10,000 replicates using
Allegro V1.2c [43] and conducted an association analysis as in the
original dataset. An empirical significance level was calculated as the
proportion of replicates for which the maximum v2 score was greater
than that obtained in the real dataset. All p-values are two-sided,
significance was defined as statistical evidence expected to occur 0.05
times at random in the analysis. For multipoint analysis, we used the
FBAT tools package [44] to generate haplotypes and performed
family-based association tests for five marker haplotypes using the
empirical variance option to adjust for correlation among sibling
genotypes. To evaluate parent-of-origin effects in the multipoint
analysis, we estimated haplotypes using MERLIN, recoded the
haplotypes as alleles, and performed the sib_TDT using ASPEX.
In silico protein analysis. Protein sequences were retrieved from
the UniProt (http://www.uniprot.org) and Ensembl (http://www.
ensembl.org) databases. The domain architecture of the collagen
XXIX protein was retrieved from the NCBI conserved domain search
website (http://www.ncbi.nlm.nih.gov:80/Structure/cdd/wrpsb.cgi). The
following domains were found in collagen XXIX and analyzed further:
cd01472 (vWA_collagen), cd01450 (vWFA_subfamily_ECM),
cd01470 (vWA_complement_factors), cd01465 (vWA_subgroup),
and Pfam01391 (collagen triple helix repeat). To predict the 3D
structure of the vWF protein domains in collagen XXIX, we explored
the structure prediction results returned by the web servers
GenTHREADER (http://bioinf.cs.ucl.ac.uk/psipred/) and FFAS03
(http://ffas.ljcrf.edu). Based on their very similar predictions, the
human vWF A3 domain was chosen as the structural template to
analyze the position of COL29A1 SNPs in 3D and to predict their
potential effect on protein function.
Exon identification and characterization of the collagen XXIX
gene. A 2447-bp sequence from a human testis cDNA library which
covered eight exons was the starting point for the characterization of
COL29A1. Using rapid amplification of cDNA ends together with the
Model Maker of NCBI, we identified a total of 42 exons and
determined the transcription start site as well as the 39 end of the
COL29A1 transcript in cDNA from human skin. The complete
sequence of the transcript was confirmed by cloning and sequencing
of the full-length cDNA. To explore the potential gene function of
COL29A1, the protein sequence was predicted (http://us.expasy.org/
tools/dna.html), a domain search was performed (http://www.sanger.
ac.uk/Software/Pfam/search.shtml) [45], and the presence and location
of signalling peptides was analyzed (http://www.cbs.dtu.dk/services/
SignalP/) [46].
Gene expression analysis. We examined tissue-specific expression
of COL29A1 using oligo(dT)-primed cDNA of 17 different human
tissues. cDNA samples of 16 tissues were from the human MTC Panels I
and II, which are standardized for the expression of GAPDH (BD
Biosciences; http://www.bdbiosciences.com). In addition, human skin
poly(A)þ RNA (BD Biosciences) was transcribed into cDNA using the
Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics;
http://www.roche.com). PCR was performed using COL29A1-specific
primers 59-GTTCTAACCAGAATGTATAATCATC (forward) and
59-TAATTCCCAAGAACATCTCTGGT (reverse), yielding a product
of 694 bp, and the GAPDH control primers supplied with the MTC
panels.
For in situ hybridization, we generated a plasmid by cloning a
COL29A1-specific PCR product amplified from human skin cDNA
[59-ACCTTAGGAGACAGGGTTGCT (forward); 59-AGTTC-
CAATCTGGCTTGTGG (reverse)] into the pCRII vector (Invitrogen;
http://www.invitrogen.com). We synthesized antisense and sense
digoxigenin-labeled riboprobes using the Dig RNA Labeling Kit
(Roche Diagnostics). Punch biopsies of human skin were obtained
from five AD patients and five healthy donors, immediately fixed in 4%
paraformaldehyde for 4 h, cryoprotected in 30% sucrose overnight,
and embedded in Tissue-Tek (Sakura; http://www.sakura.com) for
cryosectioning. 10 lm cryosections were mounted on slides and dried
for 15 min at 50 8C. Sections were postfixed in 4% paraformaldehyde
for 7 min at 4 8C and acetylated with 0.25% acetic acid for 10 min.
Sections were prehybridized for 3 h and hybridized overnight at 50 8C
with digoxigenin-labeled riboprobes. After hybridization, sections
were washed twice with 23SSC at 53 8C and once with 0.13SSC at 58
8C. For detection of the hybridized probe, slides were incubated with
BCIP/NBT staining solution (Roche Diagnostics) for 4 d according to
the manufacturer’s recommendations.
To quantify gene expression in skin specimens, total RNA was
isolated from 160 lm cryosections of skin biopsies using the RNeasy
Mini Kit (Qiagen; http://www.qiagen.com). RNA was reverse tran-
scribed into cDNA with random hexamer primers using the Tran-
scriptor First Strand cDNA Synthesis Kit (Roche Diagnostics). Taqman
real-time PCR was performed with iTaq SYBR Green (BioRad; http://
www.biorad.com) and gene-specific PCR products were detected on
the ABI PRISM 7900 sequence detection system (Applied Biosystems).
All measurements were performed in duplicate. COL29A1 expression
was normalized for 18S rRNA expression. Differences in gene
expression were calculated using the DDct method and were expressed
as fold change. Gene-specific primers were as follows; COL29A1-
forward, 59-CCACCCTCTGGATCATCACT, COL29A1-reverse,
59-GTTTTCTGTGCCACCGTTCT, KRT10-forward, 59-CTGAAACC-
GAGTGCCAGAAT, KRT10-reverse, 59-GCCTCCGGAACTTCCCTCT,
18S rRNA-forward, 59-GGATGCGTGCATTTATCAGA, 18S rRNA-
reverse, 59-GATCAGCCCGAGGTTATCTA. The sizes of the PCR
products were confirmed by gel electrophoresis and the specificity
of the reaction was confirmed by melting curve analysis of the PCR
products. For statistical analysis, the unpaired t-test was used.
Antibodies and immunohistochemistry. A polyclonal antibody
against human collagen XXIX protein was raised by immunizing
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rabbits with a collagen XXIX specific peptide (SLGSTRKDDMEELAC,
residues 2115–2128) (Eurogentec; http://www.eurogentec.com). The
specificity of the antibodies purified by affinity chromatography was
tested by comparing their reactivity against recombinant proteins by
Western blotting and by blocking experiments.
For immunohistochemistry, freshly isolated skin specimens from
five AD patients and five healthy individuals were embedded in
Tissue-Tek. Cryosections of 5 lm thickness were prepared and fixed
with acetone. Sections were incubated with anti-collagen XXIX
antibodies followed by dextran-coupled anti-rabbit antibody, an
alkaline phosphatase labelled amplification polymer (DAKO EnVi-
sion System; http://www.dako.com) and detection with fuchsin
(DAKO). Nuclei were counterstained with Mayer’s hematoxylin
solution (Sigma-Aldrich; http://www.sigmaaldrich.com). Omission of
primary antibody and preincubation with equimolar amount of
peptide used for generation of the antibody in rabbits were used as
negative controls for parallel sections. The results were consistent
among the AD patients on one hand, and among the control biopsies
on the other.
Supporting Information
Figure S1. Hapmap LD Data for the COL29A1 Region on Human
Chromosome 3
LD plot for the CEPH population (Utah residents with ancestry from
northern and western Europe) is shown [19]. The intensity of the
color of the red boxes represents the pairwise LD values (r2) between
two markers. Positions of the markers genotyped by the HapMap
Project are indicated by vertical dashes on the horizontal bar. The
scale indicates the physical position on Chromosome 3 in kb. Gene
loci were taken from the human genome NCBI build 36.2 and
correspond to the largest mRNA identified (FLJ35880 and
LOC131873) or were predicted (LOC646300).
Found at doi:10.1371/journal.pbio.0050242.sg001 (1.3 MB TIF).
Figure S2. Gene Expression Analysis
Gene expression analysis of COL29A1 in the epidermis of AD patients
(A) and of non-affected individuals (B). Cryosections (5 lm thick) of
skin biopsies of five AD patients (AD1 to AD5) and of five normal
human control individuals (NC1 to NC5) were hybridized with a
digoxigenin-labeled antisense probe specific for COL29A1 mRNA (on
the left) and with a digoxigenin-labeled sense probe as a negative
control (on the right). Staining of the detected transcripts was
performed with the BCIP/NBT staining solution (blue). No staining
was observed in the upper spinous and granular layer (indicated by
arrows) of AD patients. The mRNA expression pattern was in good
agreement with the results of the immunohistochemical staining of
the protein. Sections were photographed at 2003magnification (AD5,
1003).
Found at doi:10.1371/journal.pbio.0050242.sg002 (15 MB TIF).
Figure S3. Immunohistochemical Analysis
Immunohistochemical analysis of collagen XXIX expression in the
epidermis of AD patients (A) and of non-affected individuals (B).
Cryosections (5 lm thick) of skin biopsies of five AD patients (AD1–
AD4, AD6) and of five normal human control individuals (NC1–NC3,
NC6, NC7) were incubated with a rabbit polyclonal antibody against
ColXXIX epitope and stained with fuchsin (red). Counterstaining was
performed with hematoxylin (blue). Negative controls (on the right)
were lacking the primary antibody. In normal, human skin, collagen
XXIX is expressed in the epidermis with a slight increase towards the
more differentiated layers. AD patients lack the protein in the upper
spinous and granular layer as indicated by arrows. Sections were
photographed at 2003magnification (AD5, 1003).
Found at doi:10.1371/journal.pbio.0050242.sg003 (18 MB TIF).
Table S1. SNPs Used in the Association Scan in the 5.4-Mb Region
Between Markers M3CS075 and M3CS233
The average typing rate was  97.9%
Found at doi:10.1371/journal.pbio.0050242.st001 (564 KB DOC).
Table S2. Nonsynonymous Coding SNPs in COL29A1
vWA, von Willebrand factor domain; Col, collagen domain
Found at doi:10.1371/journal.pbio.0050242.st002 (113 KB DOC).
Table S3. Results of the ASPEX sib_TDT for SNPs in the Region of
COL29A1 for Allergic Sensitization in the Discovery Cohort
Found at doi:10.1371/journal.pbio.0050242.st003 (112 KB DOC).
Table S4. Association Analysis of Single Markers for Allergic
Sensitization in the Replication Dataset
Found at doi:10.1371/journal.pbio.0050242.st004 (58 KB DOC).
Table S5. Haplotype Analysis for Allergic Sensitization in the
Replication Dataset
Found at doi:10.1371/journal.pbio.0050242.st005 (49 KB DOC).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html) ac-
cession numbers for genes and proteins discussed in this paper are:
AK093199 (FLJ35880), NM 153264 (FLJ35880), and NP 476507 (human
collagen VI alpha 3 chain),
The Protein Databank (http://www.pdb.com) accession number for
the human vWF A3 domain is 1atz.
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